
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Johnson & Johnson is a drug manufacturers-general business with stocks listed in the US. Johnson And Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$106.2858 - US$172.5739 |
---|---|
50-day moving average | US$162.9809 |
200-day moving average | US$151.8363 |
Target price | US$185.44 |
PE ratio | 29.175 |
Dividend yield | US$3.98 (2.46%) |
Earnings per share (TTM) | US$5.509 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Johnson And Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson And Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson And Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Johnson And Johnson shares trade at around 29x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Johnson And Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3668. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson And Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Johnson And Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$27 billion (£19.2 billion).
The EBITDA is a measure of a Johnson And Johnson's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | US$82.6 billion |
---|---|
Operating margin TTM | 24.11% |
Gross profit TTM | US$54.2 billion |
Return on assets TTM | 7.72% |
Return on equity TTM | 23.74% |
Profit margin | 17.82% |
Book value | 24.494 |
Market capitalisation | US$423.1 billion |
TTM: trailing 12 months
There are currently 15.6 million Johnson And Johnson shares held short by investors – that's known as Johnson And Johnson's "short interest". This figure is 15.8% up from 13.5 million last month.
There are a few different ways that this level of interest in shorting Johnson And Johnson shares can be evaluated.
Johnson And Johnson's "short interest ratio" (SIR) is the quantity of Johnson And Johnson shares currently shorted divided by the average quantity of Johnson And Johnson shares traded daily (recently around 9.1 million). Johnson And Johnson's SIR currently stands at 1.71. In other words for every 100,000 Johnson And Johnson shares traded daily on the market, roughly 1710 shares are currently held short.
However Johnson And Johnson's short interest can also be evaluated against the total number of Johnson And Johnson shares, or, against the total number of tradable Johnson And Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson And Johnson's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Johnson And Johnson shares in existence, roughly 10 shares are currently held short) or 0.0059% of the tradable shares (for every 100,000 tradable Johnson And Johnson shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson And Johnson.
Find out more about how you can short Johnson And Johnson stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson And Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson And Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson And Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.79/100
Johnson And Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 25.14/100
Johnson And Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.87/100
Johnson And Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson And Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson And Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson And Johnson has a damaged public profile.
Johnson & Johnson was last rated for ESG on: 2019-01-01.
Total ESG score | 35.8 |
---|---|
Total ESG percentile | 72.38 |
Environmental score | 3.79 |
Environmental score percentile | 7 |
Social score | 25.14 |
Social score percentile | 7 |
Governance score | 14.87 |
Governance score percentile | 7 |
Level of controversy | 4 |
Dividend payout ratio: 50.31% of net profits
Recently Johnson And Johnson has paid out, on average, around 50.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.48% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson And Johnson shareholders could enjoy a 2.48% return on their shares, in the form of dividend payments. In Johnson And Johnson's case, that would currently equate to about $3.98 per share.
Johnson And Johnson's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Johnson And Johnson's most recent dividend payout was on 9 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 22 February 2021 (the "ex-dividend date").
Johnson And Johnson's shares were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson And Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson And Johnson shares which in turn could have impacted Johnson And Johnson's share price.
Over the last 12 months, Johnson And Johnson's shares have ranged in value from as little as US$106.2858 up to US$172.5739. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson And Johnson's is 0.7177. This would suggest that Johnson And Johnson's shares are less volatile than average (for this exchange).
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Sony’s PlayStation 2 changed the gaming world back in the year 2000, but right now, what are the must-have and must-play games on the platform?
Today's best Finder Daily deals include: Huge men's sneaker sale, 40% off Ray-Bans sunglasses, 47% off Apple iPhone XS.
From weight, material, features and frame to denier, recline, padding and comfort, there's plenty to think about when buying a camping chair.
He’s just trying to be a better person.
At Coyote Ugly, the party never ends.
A girl walks into a man’s life… and steals his heart.
There will be unexpected bumps on the road to growing up.
Every man dies. Not every man really lives.
Sally Hawkins shines in this remarkable fantasy drama.
This family puts the fun back in dysfunctional.